Virali Patel, MD
Internal Medicine · Indianapolis, INNPI 1851702989
Payments from drug & device makers
Across 218 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$593
- AbbVie$564
- Lilly USA, LLC$444
- AstraZeneca$241
- Pfizer$229
- Otsuka America Pharmaceutical, Inc.$168
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,676100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $593 |
| AbbVie(2 entities) | 30 | $564 |
| Lilly USA, LLC | 30 | $444 |
| AstraZeneca | 11 | $241 |
| Pfizer | 15 | $229 |
| Otsuka America Pharmaceutical, Inc. | 8 | $168 |
| Boehringer Ingelheim | 10 | $165 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $139 |
| Exact Sciences | 7 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $93 |
| Astellas Pharma US Inc | 4 | $84 |
| Phathom Pharmaceuticals, Inc. | 5 | $84 |
| Axsome Therapeutics, Inc. | 4 | $74 |
| Idorsia Pharmaceuticals US Inc | 5 | $70 |
| Vanda Pharmaceuticals Inc. | 3 | $66 |
| Novartis | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Amgen | 3 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $48 |
| Tempus AI, Inc | 2 | $46 |
| GSK | 2 | $34 |
| Halozyme Inc | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Edwards Lifesciences | 1 | $24 |
| Johnson & Johnson | 2 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Merck | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$3,676 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $72,869 |
| EliquisApixaban | 72 | $62,377 |
| MounjaroTirzepatide | 48 | $61,482 |
| JardianceEmpagliflozin | 47 | $50,294 |
| TrulicityDulaglutide | 39 | $45,551 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $40,077 |
| FarxigaDapagliflozin Propanediol | 22 | $24,128 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $23,102 |
| XareltoRivaroxaban | 15 | $22,471 |
| LinzessLinaclotide | 18 | $16,785 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $14,829 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $13,214 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $12,085 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $9,282 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 29 | $6,366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $444 | $107,03387 claims |
| Novo NordiskOzempic | $593 | $72,86962 claims |
| PfizerEliquis, Premarin, Prempro, Paxlovid | $229 | $72,735112 claims |
| Boehringer IngelheimJardiance, Glyxambi | $165 | $65,12358 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $34 | $50,835101 claims |
| AstraZenecaFarxiga | $241 | $24,12822 claims |
| Johnson & JohnsonXarelto | $23 | $22,47115 claims |
| AbbVieLinzess, Synthroid | $564 | $18,24349 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $30 | $13,21413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Indianapolis
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- Georgiann LinnemeierIndianapolis$692K
- Allon FriedmanIndianapolis$524K
- Eromonsele IdahosaIndianapolis$471K
- Misty ShieldsIndianapolis$411K
- Pei LuIndianapolis$298K
- Paul DexterIndianapolis$161K
- Jon DukeIndianapolis$138K
- Napoleon MamintaIndianapolis$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.